Sign in to continue:

Saturday, April 11th, 2026

Matthews International Corporation Signs Employment and Transition Agreement with Steven D. Gackenbach, Group President Memorialization 8




Matthews International Corporation Announces Transition Agreement with Group President, Memorialization

Matthews International Corporation Announces Leadership Transition and Key Executive Compensation Details

Key Highlights

  • Matthews International Corporation (NASDAQ: MATW) has entered into an Employment and Transition Agreement with Steven D. Gackenbach, currently serving as Group President, Memorialization.
  • The agreement outlines a planned transition of Mr. Gackenbach from his current role to Senior Advisor, with a formal part-time arrangement extending through January 2, 2028.
  • Executive compensation, bonus eligibility, and ongoing equity participation have been detailed, along with restrictive covenants, confidentiality, and non-disparagement provisions.

Detailed Overview

Leadership Transition Plan

Under the terms of the agreement, Mr. Gackenbach will continue as Group President, Memorialization, reporting directly to the CEO, until September 30, 2026. From October 1, 2026, through January 2, 2028, he will take on the role of Senior Advisor, working part-time (20 hours per week) and continuing to report to the CEO. Importantly, Mr. Gackenbach is permitted to work remotely during this period.

The total “Employment Period” as defined in the agreement runs from April 1, 2026, through January 2, 2028. Upon conclusion of the employment period, Mr. Gackenbach will transition into a consulting arrangement, previously negotiated and attached as Exhibit A to the agreement, for no less than two years.

Executive Compensation and Incentives

  • Base Salary: Mr. Gackenbach will receive an annual base salary of \$562,500 through September 30, 2026, paid in regular installments. From October 1, 2026, his salary will be reduced to 50% of the base salary in effect as of September 30, 2026, reflecting his part-time status.
  • Merit Increase: In January 2027, he will be eligible for a merit-based salary increase aligned with the Company’s targeted merit percentage for executive leadership, subject to approval by the Board’s Compensation Committee.
  • Annual Bonus: Mr. Gackenbach remains eligible to participate in the Company’s Management Incentive Plan, with a target annual bonus opportunity equal to 60% of base salary through September 30, 2026. The actual bonus may vary depending on Company performance. Bonuses are subject to proration if employment terminates during the fiscal year.
  • Equity Compensation: The executive remains eligible for equity compensation during the term of the agreement and will continue to be bound by the restrictive covenants in prior restricted stock unit (RSU) agreements.
  • Employee Benefits: Mr. Gackenbach remains eligible for all company employee benefits, including enhanced benefits available to executive leaders. Notably, he will also receive retiree life insurance coverage with all premiums paid by the company.

Restrictive Covenants and Other Provisions

  • Confidentiality and Non-Competition: The agreement includes robust confidentiality clauses, prohibiting Mr. Gackenbach from disclosing or using the company’s nonpublic, proprietary, or confidential information. He is also subject to non-competition and non-solicitation agreements.
  • Non-Disparagement: Both the Company and Mr. Gackenbach have agreed not to make any disparaging statements about each other, with limited exceptions for legal testimony or disclosures as required by law.
  • Return of Company Property: Upon termination, Mr. Gackenbach must return all company property and records.
  • Section 409A Compliance: The agreement is intended to comply with IRS Section 409A, and any payments due on termination will be structured to avoid adverse tax consequences.

Potential Shareholder and Price-Sensitive Implications

  • Leadership Transition: The planned and orderly transition of a key divisional President to an advisory and then consulting capacity may be viewed positively by investors, as it facilitates knowledge transfer and maintains continuity in leadership.
  • Compensation Structure: The detailed compensation structure, including significant retention through both salary and bonus, as well as continued equity eligibility, reflects the company’s commitment to retaining executive expertise during the transition.
  • No Emerging Growth Company Status: The filing confirms Matthews International is not classified as an Emerging Growth Company, which may affect certain regulatory and reporting requirements.
  • Legal Protections: The inclusion of strong restrictive covenants, confidentiality, and non-disparagement provisions are designed to protect the company’s intellectual property and competitive position during and after the executive’s transition.

Conclusion

The execution of this Employment and Transition Agreement represents a significant leadership transition for Matthews International Corporation’s Memorialization segment. Investors should note the structured approach to executive succession, the retention of key talent in an advisory and consulting capacity, and the robust compensation and legal protections designed to ensure continuity and protect company interests.

While the transition appears to be well-planned and not abrupt, such changes in senior management can affect strategic direction, operational execution, and potentially investor sentiment. The market may react to the perceived stability and succession planning, or may scrutinize the company’s performance during the transition period.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. The author and publisher are not responsible for any actions taken based on the information contained herein.




View MATTHEWS INTERNATIONAL CORP Historical chart here



Pulse Biosciences, Inc. Form 8-K Filing Details (Feb. 27, 2026) – Company, Stock, and Regulatory Information

Pulse Biosciences, Inc. 8-K Filing: Executive Resignation An...

KLX Energy Services Holdings, Inc. 2025 Annual Report: Business Overview, Industry Risks, and Competitive Strategies

KLX Energy Services Holdings, Inc. 2025 Annual Report: Key H...

Zymeworks Inc. 2025 Annual Report: Business Overview, Strategy, Risk Factors, and Pipeline Highlights

Zymeworks Inc. 2025 Annual Report: Key Highlights for Invest...

   Ad